Optimization of a series of N-1-cycloalkyl-4-aryl-5-(pyrimidin-4-yl)imidazo
le inhibitors of p38 kinase is reported. Oral administration of inhibitors
possessing a cyclohexan-4-ol or piperidin-4-yl group at N-1 in combination
with alkoxy, amino(alkyl), phenoxy and anilino substitution at the 2-posit
ion of the pyrimidine was found to potently inhibit LPS-induced TNF in mice
and rats. T e selectivity of these new inhibitors for p38 kinase versus ei
ght other protein kinases is high and in all cases exceeds that of SB 20358
0. (C) 2001 Elsevier Science Ltd. All rights reserved.